scholarly journals The plant secondary compound swainsonine reshapes gut microbiota in plateau pikas (Ochotona curzoniae)

2021 ◽  
Author(s):  
Shien Ren ◽  
Chao Fan ◽  
Liangzhi Zhang ◽  
Xianjiang Tang ◽  
Haibo Fu ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Artificial Diet ◽  
Alpha Diversity ◽  
Term Treatment ◽  
Short Term Treatment ◽  
Ochotona Curzoniae ◽  
Rdna Sequencing ◽  
Long Term Treatment ◽  
Significant Difference ◽  
Herbivorous Mammals

Abstract Plants produce various plant secondary compounds (PSCs) to deter the foraging of herbivorous mammals. However, little is known about whether PSCs can reshape gut microbiota and promote gut homeostasis of hosts. Using 16S rDNA sequencing to investigate the effects of PSCs on the gut microbiota of small herbivorous mammals, we studied plateau pikas (Ochotona curzoniae) fed diets containing swainsonine (SW) extracted from Oxytropis ochrocephala. Our results showed that both long- and short-term treatment of a single artificial diet in the laboratory significantly reduced alpha diversity and significantly affected beta diversity, core bacteria abundance, and bacterial functions in pikas. After SW was added to the artificial diet, the alpha diversity significantly increased in the long-term treatment, and core bacteria (e.g., Akkermansiaceae) with altered relative abundances in the two treatments showed no significant difference compared with pikas in the wild. The complexity of the co-occurrence network structure was reduced in the artificial diet, but it increased after SW was added in both treatments. Further, the abundances of bacteria related to altered alanine, aspartate, and glutamate metabolism in the artificial diet were restored in response to SW. SW further decreased the concentration of short-chain fatty acids (SCFAs) in both treatments. Our results suggest that PSCs play a key role in regulating gut microbiota community and intestinal homeostasis, thereby maintaining host health. Key points • Swainsonine improves the intestinal bacterial diversity of plateau pikas. • Swainsonine promotes the recovery of core bacterial abundances in the gut of plateau pikas. • Swainsonine promotes the restoration of intestinal bacterial functions of plateau pikas.

scholarly journals Stable Colonization of Orally Administered Lactobacillus casei SY13 Alters the Gut Microbiota

2020 ◽  
Vol 2020 ◽  
pp. 1-8 ◽  
Author(s):  
Yuanchun Yue ◽  
Xiaoxi Xu ◽  
Baoyu Yang ◽  
Jing Lu ◽  
Shuwen Zhang ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Oral Administration ◽  
Lactobacillus Casei ◽  
Illumina Miseq ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Long Term Treatment ◽  
Colonization Ability

The gut microbiota plays an important role in intestinal health. Probiotics such as Lactobacillus are known to regulate gut microbes and prevent diseases. However, most of them are unable to colonize their stability in hosts’ intestinal tracts. In this study, we investigated the ability of Lactobacillus casei SY13 (SY13) to colonize the intestinal tract of BALB/c mice, after its oral administration for a short-term (once for a day) and long-term (once daily for 27 days) duration. Furthermore, we also evaluated the influence of its administration on the gut microbial structure and diversity in mice. Male BALB/c mice were gavaged with 108 colony-forming units (CFU) of SY13, and TaqMan-MGB probe and Illumina MiSeq sequencing were performed to assess the colonization ability and bacterial community structure in the cecum contents. The results showed that long-term treatment with SY13 enhanced its ability to form a colony in the intestine tract in contrast to the short-term treatment group, whose colony was retained for only 3 days. Oral administration of SY13 also significantly enhanced the gut microbial diversity. Short-term treatment with SY13 (SSY13) elevated Firmicutes and diminished Bacteroidetes phyla compared with long-term treatment (LSY13) and controls. The findings laid the foundation for the study of probiotic colonization ability and improvement of microbiota for the prevention of gut diseases.

scholarly journals Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Juan Li ◽  
Chunhua Hu ◽  
Yi Chen ◽  
Rou Zhang ◽  
Shan Fu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Term Treatment ◽  
Efficacy And Safety ◽  
Short Term ◽  
Serum Cystatin C ◽  
Short Term Treatment ◽  
Link Type ◽  
Long Term Treatment ◽  
Significant Difference

Abstract Background & Aims There is limited evidence on the efficacy and safety of nucleos(t) ide analogues (NAs) in the treatment of HBV-ACLF. Our objective was to evaluate the outcomes among TAF, TDF and ETV, three first-line antivirals against chronic hepatitis B, in patients with HBV-ACLF. Methods Patients with HBV-related ACLF were recruited and received daily TAF (25 mg/d), TDF (300 mg/d) and ETV (0.5 mg/d). They were prospectively followed-up. The primary endpoint was overall survival at week 12 and week 48, the secondary endpoints were virological response and biochemical response. Results Forty gender and age matched eligible subjects were recruited and divided into three groups: TAF group, TDF group and ETV group. By week 48, 8 (80%) patients in TAF group, 6 (60%) patients in TDF group and 17 (85%) patients in ETV group survived without liver transplantation (P = 0.251). After 4 weeks of NAs treatment, all three groups showed paralleling reduction of HBV DNA levels. All three groups presented similar biochemical responses at week 4, patients treated with TAF showed a priority in total bilirubin reduction, albumin and cholesterol maintenance. Additionally, although there was no significant difference in changes of serum urea, serum creatinine, serum cystatin C and estimated GFR among the three groups by treatment week 4, TDF showed unfavorable renal safety even in short -term treatment. The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported. Conclusions TAF, TDF and ETV are of similar efficacy and safety in short-term and long-term treatment of HBV-ACLF. Trial registration This study is ongoing and is registered with ClinicalTrials.gov, NCT03640728 (05/02/2019).

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute‐on‐chronic liver failure associated with hepatitis B

2021 ◽  
Author(s):  
Juan Li ◽  
Chunhua Hu ◽  
Yi Chen ◽  
Rou Zhang ◽  
Shan Fu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Similar Efficacy ◽  
Term Treatment ◽  
Efficacy And Safety ◽  
Short Term ◽  
Serum Cystatin C ◽  
Short Term Treatment ◽  
Long Term Treatment ◽  
Significant Difference

Abstract Background & Aims: There is limited evidence on the efficacy and safety of nucleos(t)ide analogues (NAs) in the treatment of HBV-ACLF. Our objective was to evaluate the outcomes among TAF, TDF and ETV, three first-line antivirals against chronic hepatitis B, in patients with HBV-ACLF. Methods: Patients with HBV-related ACLF were recruited and received daily TAF (25mg/d), TDF (300 mg/d) and ETV (0.5 mg/d). They were prospectively followed-up. The primary endpoint was overall survival at week 12 and week 48, the secondary endpoints were virological response and biochemical response. Results: Forty gender and age matched eligible subjects were recruited and divided into three groups: TAF group, TDF group and ETV group. By week 48, 8 (80%) patients in TAF group, 6 (60%) patients in TDF group and 17 (85%) patients in ETV group survived without liver transplantation (P = 0.251). After 4 weeks of NAs treatment, all three groups showed paralleling reduction of HBV DNA levels. All three groups presented similar biochemical responses at week 4, patients treated with TAF showed a priority in total bilirubin reduction, albumin and cholesterol maintenance. Additionally, although there was no significant difference in changes of serum urea, serum creatinine, serum cystatin C and estimated GFR among the three groups by treatment week 4, TDF showed unfavorable renal safety even in short term treatment. The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported. Conclusions: TAF, TDF and ETV are of similar efficacy and safety in short-term and long-term treatment of HBV-ACLF. This study is ongoing and is registered with ClinicalTrials.gov, NCT03640728 (05/02/2019).

scholarly journals Combination treatment with valsartan and amlodipine intensifies evening suppression of Bmal1 clock gene in kidneys of spontaneously hypertensive rats

2017 ◽  
Vol 64 (1) ◽  
pp. 22-25
Author(s):  
P. Potucek ◽  
M. Radik ◽  
G. Doka ◽  
E. Kralova ◽  
P. Krenek ◽  
...  
Keyword(s):  
Spontaneously Hypertensive Rats ◽  
Clock Gene ◽  
Term Treatment ◽  
Hypertensive Rats ◽  
Short Term ◽  
Short Term Treatment ◽  
Spontaneously Hypertensive ◽  
Long Term Treatment ◽  
Significant Difference

AbstractBlood pressure (BP) rhythm is exhibited in a circadian pattern regulated by complex system of endogenous factors. Administration of pharmacological treatment at the right time can influence the efficacy of treatment; but while kidneys play significant role in BP regulation, little is known about their role in chronopharmacotherapy. This study aimed to compare differences between morning and evening dosing with valsartan and amlodipine combination in both short-term and long-term settings and to elucidate the role of kidneys in chronopharmacology. Spontaneously hypertensive rats aged between 8 and 10 weeks were daily treated with 10mg/kg of valsartan and 4 mg/kg of amlodipine, either in the morning or in the evening with treatment duration of 1 and 6 weeks. After short-term treatment, only morning treatment group demonstrated significantly better outcomes in terms of BP control when compared to placebo. After long-term treatment, both treatment groups gained superior results in BP control against placebo; however, no significant difference was seen between morning and evening treatment. Interestingly, clock gene expression in kidney has been significantly modulated only in the evening-treated groups, with treatment intensifying the reduced Bmal1 levels, while Per2 expression was less altered. However, no direct relation with the outcomes of the therapy has been observed, suggesting that pharmacotherapy may serve as an independent modulator of peripheral circadian clock in the kidney.

Anticancer Effects & Comparative Study of Thymoquinone, Cordyceps, Spirulina, Ganoderma Lucidium, Poria Cocos, and Lion’s Mane on Human Nasal Cancer Cells (RPMI-2650)

2020 ◽  
pp. 62-78
Author(s):  
سعيد مزعل موازي ◽  
يحيى فائق حسين ◽  
عبد المنعم دولاني ◽  
سيف يوسف عبدالله السويدي
Keyword(s):  
Term Treatment ◽  
Epithelial Cell Line ◽  
Anticancer Effect ◽  
Short Term Treatment ◽  
Poria Cocos ◽  
Nasal Cancer ◽  
Antineoplastic Effect ◽  
Long Term Treatment ◽  
High Concentrations

Recently, many studies have been conducted to discover or improve cancers treatment. The current study aims to investigate the anticancer effect of thymoquinone, cordyceps, spirulina, ganoderma lucidium, poria cocos, and lion’s mane in four different concentrations 4, 8, 16, and 32 ug (equivalent to 1 mg/mL) in two different time treatments (48 and 96 hours) on human nasal epithelial cell line RPMI 2650. By using cell culture cytotoxicity techniques and assay, the highest anticancer effect on RPMI 2650 was obtained by thymoquinone. The lowest anticancer effect was demonstrated by poria cocos and cordyceps. However, these two medications showed higher anticancer effect when given in short-term treatment (48 hours) compared to long-term treatment (96 hours). Ganoderma lucidium and spirulina showed better impact than poria cocos, cordyceps, and lion’s mane in term of cells cytotoxicity. Mild to moderate antineoplastic effect was seen by utilizing lion’s mane treatment compared other drugs. Therefore, adopting a long-term treatment of high concentrations and doses of thymoquinone, cordyceps, spirulina, ganoderma lucidium, poria cocos, and lion’s mane can be more effective in the treatment of nasal cancer. In conclusion, these drugs were found to be a promising cancer remedy; therefore, they can be utilized as alternative treatment for nasal cancer or any other type of cancer therapy.

scholarly journals Rivaroxaban for the treatment of cerebral venous thrombosis

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sara Esmaeili ◽  
Meysam Abolmaali ◽  
Sobhan Aarabi ◽  
Mohammad Reza Motamed ◽  
Samira Chaibakhsh ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Bleeding Risk ◽  
Term Treatment ◽  
Background Information ◽  
Minor Bleeding ◽  
Long Term Treatment ◽  
Significant Difference

Abstract Background New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebral venous thrombosis (CVT). This study aims to assess the effectiveness and bleeding risk of Rivaroxaban in comparison with Warfarin for the treatment of CVT. Materials and methods 36 patients with diagnosis of CVT were included. Clinical and background information was assessed on admission and patients were followed for at least 12 months. Measured outcomes were modified Rankin Scale (mRS), evidence of recanalization on contrast-enhanced Brain MR venography (MRV) and major or minor bleeding. Patients were divided into two groups according to the type of oral anticoagulant (Rivaroxaban vs Warfarin). Groups were compared in terms of final outcomes and side effects. Result Overall, 13 (36.11%) patients received Warfarin and 23 (63.89%) received Rivaroxaban. Optimal mRS score (0–1) was attained in 9 of 10 (90%) of patients treated with Rivaroxaban and 19 of 22 (86.36%) of patients received Warfarin. MRV showed complete or partial recanalization in 12 of 14 (85.71%) patients treated with Rivaroxaban and all patients in the Warfarin group. There was no significant difference between the two groups in terms of major and minor hemorrhage. Conclusion Rivaroxaban holds promise for the treatment of CVT.

Fluvoxamine in the Treatment of Trichotillomania: An 8-Week, Open-Label Study

CNS Spectrums ◽  
1998 ◽  
Vol 3 (9) ◽  
pp. 64-71 ◽  
Author(s):  
Gary A. Christenson ◽  
Scott J. Crow ◽  
James E. Mitchell ◽  
Thomas B. Mackenzie ◽  
Ross D. Crosby ◽  
...  
Keyword(s):  
Treatment Response ◽  
Term Treatment ◽  
Hair Pulling ◽  
Short Term ◽  
Open Label ◽  
Short Term Treatment ◽  
Open Label Study ◽  
Label Study ◽  
Long Term Treatment

AbstractThis short-term, open-label study investigates short- and long-term effects of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine for the treatment of trichotillomania (TTM). Additionally, this study aimed to test the hypothesis that the presence of hair pulling compulsiveness is predictive of SSRI response. Nineteen subjects meeting the Diagnostic and Statistical Manual of Mental Disorders, Third Edition Revised, (DSM-III-R) criteria for TTM were treated with fluvoxamine at doses up to 300 mg/day. Random regression analysis of change across time for patients who completed the study (n=14) and those who dropped out (n=5) revealed statistically significant improvements in Physician Rating Scale, hair-pulling episodes, Trichotillomania Impairment Scale, and Trichotillomania Symptom Severity Scale, but not in estimated amount of hair pulled. In addition, the percentage of patients' focused or compulsive hair-pulling symptoms was predictive of treatment response. Unfortunately, all three subjects who entered long-term treatment displayed substantial movement back toward baseline by the end of 6 months. We concluded that fluvoxamine produces moderate reductions in symptoms during the short-term treatment of TTM and that the presence of focused or compulsive hair pulling may be predictive of treatment response. However, responses may be short lived when treatment is extended.

scholarly journals Diversity in the intestinal microbiota and the influence of delivery, dietary profile and nutritional status

2021 ◽  
Vol 2 (5) ◽  
Author(s):  
Franciele Valduga ◽  
◽  
Malena Rostirola Miri ◽  
Daniela Signori ◽  
Larissa Pereira da Costa ◽  
...  
Keyword(s):  
Nutritional Status ◽  
Gut Microbiota ◽  
School Children ◽  
Alpha Diversity ◽  
Grape Juice ◽  
Anthropometric Parameters ◽  
Culture Methods ◽  
Normal Delivery ◽  
Significant Difference ◽  
Microbiota Diversity

Objective: This research aimed to evaluate the nutritional status and influence on the dietary profile in the gut microbiota, in an attempt to identify possible effects of grape juice consumption among school children aged 6-10. Design: Anthropometric parameters (weight, height, Body Mass Index, waist circumference, triceps, and subscapular skinfold) weremeasured at baseline. A Food Frequency Questionnaire (FFQ) was carried out to evaluate the dietary profile. Feces were analyzed by culture methods and the alpha diversity was determined by the Shannon Index. Participants: 36 volunteer school children aged 6 to 10 years from two different cities in the South of Brazil. Main outcome measure: Gut microbiota diversity according to anthropometric parameters, nutrition profile and delivery patterns. Analysis: For statistical analysis, t or u test and correlation were used through the statistical software SPSS® version 22.0. Results: The volunteers presented a eutrophic nutritional status, but 41.7% in the City 2 were overweight. There was a significant difference in the consumption of polyphenols (p<0.003), microbiotadiversity, breastfeeding, and delivery patterns by city. However, the dietary profile does not include the portions of daily nutrients recommended in both cities. The volunteers from City 1 presented a greater alpha diversity, which may be related to higher micronutrient intake, breastfeeding, and predominant natural/vaginal delivery Conclusion: We observed that the normal delivery and the dietary profile seems to be important factors to the gut microbiota diversity in these children. Keywords: grape juice; dietary profile; gut microbiota.

scholarly journals The Studies to correlation between gut microbiota diversity and functional erectile dysfunction

2021 ◽  
Author(s):  
Qiang Geng ◽  
Shaofeng Chen ◽  
Yuan Sun ◽  
Yu Zhao ◽  
Zhong Li ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Gut Microbiota ◽  
Alpha Diversity ◽  
T Test ◽  
Data Quality Control ◽  
Sequencing Data ◽  
Significant Difference ◽  
Miseq Platform ◽  
Group 3 ◽  
Microbiota Diversity

Abstract Objective: To analyze the distribution of gut microbiota in the ED patients, and explore the relationship between the diversity of gut microbiota and psychogenic erectile dysfunction. Methods: 30 cases of patients with erectile dysfunction (ED) and 30 healthy persons (healthy donor, HD) stool specimen were collected, using Illumina's Miseq platform samples V3-V4 region sequences bacterial 16SrRNA gene Paired end (PE) 300 sequencing, sequencing results were analyzed differences in species composition and diversity. Analysis contains five modules: sequencing data quality control, OTU species clustering and annotation, alpha diversity, beta diversity and the use of T-test and the analysis of the LEfSe differences. Results: 1. The flora diversity in the group of ED than HD significantly different (P<0.01), ED group has a low bacterial diversity. 2. Between ED group and HD group, abundant bacteria (TOPlO) and core flora (90%) had no significant difference in the genus level; all bacteria flora (>1%) display, Alloprevotella groups genus presents differences, Alloprevotella only be identified in the HD group. 3. ED and HD groups present in well separated PCoA analysis, having a significant difference in the two kinds of microflora. 4.T-test shows six species were significantly different, in the ED group, Streptococcus and Subdoligranulum were increasing, and Prevotella, Prevotella sp.9, Blautia, Lachnospiraceae NK4A136 groups and Roseburia were decreasing. 5.LEfSe analysis revealed 24 species were significantly different between ED and HD groups. Conclusion: Gene sequencing was performed on the two groups of specimens and finding that microbial community structure and diversity had significant difference, suggesting that ED have low gut microbiota diversity.

scholarly journals Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study

2021 ◽  
Vol 14 ◽  
pp. 175628642110356
Author(s):  
Andreas Totzeck ◽  
Elakiya Ramakrishnan ◽  
Melina Schlag ◽  
Benjamin Stolte ◽  
Kathrin Kizina ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Myasthenia Gravis ◽  
Healthy Volunteers ◽  
Alpha Diversity ◽  
Diversity Indices ◽  
Rrna Gene ◽  
Pilot Studies ◽  
Variable Regions ◽  
Alpha And Beta Diversity ◽  
Significant Difference

Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disease, with gut microbiota considered to be a pathogenetic factor. Previous pilot studies have found differences in the gut microbiota of patients with MG and healthy individuals. To determine whether gut microbiota has a pathogenetic role in MG, we compared the gut microbiota of patients with MG with that of patients with non-inflammatory and inflammatory neurological disorders of the peripheral nervous system (primary endpoint) and healthy volunteers (secondary endpoint). Methods: Faecal samples were collected from patients with MG ( n = 41), non-inflammatory neurological disorder (NIND, n = 18), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP, n = 6) and healthy volunteers ( n = 12). DNA was isolated from these samples, and the variable regions of the 16S rRNA gene were sequenced and statistically analysed. Results: No differences were found in alpha- and beta-diversity indices computed between the MG, NIND and CIDP groups, indicating an unaltered bacterial diversity and structure of the microbial community. However, the alpha-diversity indices, namely Shannon, Chao 1 and abundance-based coverage estimators, were significantly reduced between the MG group and healthy volunteers. Deltaproteobacteria and Faecalibacterium were abundant within the faecal microbiota of patients with MG compared with controls with non-inflammatory diseases. Conclusion: Although the overall diversity and structure of the gut microbiota did not differ between the MG, NIND and CIDP groups, the significant difference in the abundance of Deltaproteobacteria and Faecalibacterium supports the possible role of gut microbiota as a contributor to pathogenesis of MG. Further studies are needed to confirm these findings and to develop possible treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document